Organigram Global (STU:0OG) Altman Z2-Score: 0.46 (As of Jun. 30, 2026) — 92% Below Median


STU:0OG Organigram Global Inc STU:0OG
64 GF Score
Price €0.88
GF Value €1.47
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Organigram Global Altman Z2-Score?

Organigram Global STU:0OG +0.23% 64 Altman Z2-Score is 0.46 as of Jun. 30, 2026, which is 92% below its 10-year median of 5.74. GuruFocus rates STU:0OG with a GF Score™ of 64/100 and a GF Value™ of €1.47 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 994 Drug Manufacturers companies, Organigram Global ranks worse than 75.45% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Organigram Global has a Altman Z2-Score of 0.46, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Organigram Global's Altman Z2-Score or its related term are showing as below:

STU:0OG' s Altman Z2-Score Range Over the Past 10 Years
Min: -6.21   Med: 5.74   Max: 14.53
Current: 0.45

During the past 13 years, Organigram Global's highest Altman Z2-Score was 14.53. The lowest was -6.21. And the median was 5.74.


Organigram Global  (STU:0OG) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Organigram Global Altman Z2-Score Related Terms


Organigram Global Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Organigram Global's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organigram Global Altman Z2-Score Chart

Organigram Global Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Sep24 Sep25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.19 6.39 7.82 1.10 -0.42

Organigram Global Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.80 0.92 -0.42 0.85 0.45

STU:0OG vs ZTS, UTHR: Altman Z2-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Organigram Global's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organigram Global Altman Z2-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organigram Global's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Organigram Global's Altman Z2-Score falls into.


STU:0OG
64GF Score
Organigram Global Inc STU:0OG
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organigram Global Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Organigram Global's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.3095+3.26*-1.1311+6.72*-0.0736+1.05*2.487
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was €328.7 Mil.
Total Current Assets was €157.7 Mil.
Total Current Liabilities was €56.0 Mil.
Retained Earnings was €-371.8 Mil.
Pre-Tax Income was -0.581 + 12.362 + -25.697 + -10.274 = €-24.2 Mil.
Interest Expense was 0 + 0 + 0 + 0 = €0.0 Mil.
Total Liabilities was €94.3 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(157.671 - 55.951)/328.67
=0.3095

X2=Retained Earnings/Total Assets
=-371.773/328.67
=-1.1311

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-24.19 - 0)/328.67
=-0.0736

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(234.415 - 0)/94.255
=2.487

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Organigram Global has a Altman Z2-Score of 0.46 indicating it is in Distress Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 0.46 mean?
Organigram Global (STU:0OG) has a Altman Z2-Score of 0.46 as of Jun. 30, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Organigram Global and its competitors. This is 92% below median its historical median of 5.74. According to the industry distribution chart, Organigram Global ranks #750 out of 994 companies in the Drug Manufacturers industry, placing it in the top 75.5%.
Is Organigram Global's Altman Z2-Score too high?
Organigram Global's current Altman Z2-Score of 0.46 is 92% below median its 10-year median of 5.74. The Drug Manufacturers industry median Altman Z2-Score is 3.87. Organigram Global's value of 0.46 is 88.1% below this industry median. Based on the distribution chart, Organigram Global ranks #750 out of 994 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Organigram Global has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Organigram Global's Altman Z2-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Organigram Global ranks #750 out of 994 companies for Altman Z2-Score. This places Organigram Global in the lower half of its industry. The industry median Altman Z2-Score is 3.87. Organigram Global's value of 0.46 is 88.1% below this benchmark. While the company's 10-year median is 5.74 vs. the industry median of 3.87, Organigram Global has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.87, based on 994 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organigram Global's current Altman Z2-Score of 0.46 is 88.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Organigram Global and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organigram Global's current Altman Z2-Score is 0.46, which is 92% below median its own 10-year median of 5.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organigram Global stock overvalued right now?
Based on GuruFocus' analysis, Organigram Global (STU:0OG) is currently considered Possible Value Trap. The stock's GF Value™ is €1.47, compared to a current price of €0.88 — trading 40.1% below its estimated fair value. The current Altman Z2-Score is 0.46, which is 92% below median its 10-year median of 5.74 and 88.1% below the Drug Manufacturers industry median of 3.87. Organigram Global's overall GF Score™ is 64/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Organigram Global (STU:0OG), the current Altman Z2-Score is 0.46 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organigram Global (STU:0OG) Overvalued in 2026?

Based on GuruFocus' analysis, Organigram Global stock appears to be undervalued. The current stock price of €0.88 is trading 40.1% below its estimated GF Value™ of €1.47. GuruFocus considers Organigram Global to be Possible Value Trap.

Key valuation signals for STU:0OG:

  • Altman Z2-Score: 0.46 (92% below median its 10-year median of 5.74)
  • GF Value™: €1.47 vs. price of €0.88 (40.1% below fair value)
  • GF Score™: 64/100 with 1 warning sign
  • Industry Position: 88.1% below the Drug Manufacturers median (#750 of 994)

No single metric tells the full story. See the STU:0OG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Organigram Global Business Description

Other Exchanges OGI:USAOGI:Canada
Address 145 King Street West, Suite 1400, Toronto, ON, CAN, M5H 1J8
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
64GF Score

Get the complete analysis for STU:0OG

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.88
Price
€1.47
GF Value